Insulin oral - Oramed Pharmaceuticals

Drug Profile

Insulin oral - Oramed Pharmaceuticals

Alternative Names: Orally ingestible insulin capsule - Oramed Pharmaceuticals; ORMD-0801

Latest Information Update: 17 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Oramed Pharmaceuticals
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Type 1 diabetes mellitus; Type 2 diabetes mellitus

Most Recent Events

  • 14 Nov 2017 Israel's Ministry of Health approves IND application for Insulin oral in Non-alcoholic Fatty Liver Disease
  • 31 Oct 2017 European Patent Organisation issues notice of intent to grant a patent to Oramed for Insulin oral
  • 05 Sep 2017 Oramed plans a three-month clinical trial in Type 2 diabetes
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top